Verrica Pharmaceuticals (VRCA) Climbs on FDA's NCE Status Announcement for Ycanth
Tuesday, 26 March 2024, 17:33
Verrica Pharma Soars after FDA Grants NCE Status to Ycanth in Orange Book
Verrica Pharmaceuticals (VRCA) experienced a surge in its stock price following the FDA's decision to grant New Chemical Entity (NCE) status to Ycanth. The FDA's listing of this antiviral in the Orange Book with five years of market exclusivity has positioned Verrica Pharma for significant growth in the pharmaceutical industry. This milestone underscores the potential of Ycanth and highlights Verrica's strong market position.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.